Opioid Quota Reform Act
This bill amends the Controlled Substances Act to require the Drug Enforcement Administration (DEA) to consider additional factors—the impact on overall public health and rates of diversion, abuse, and overdose deaths—in setting and adjusting production and manufacturing quotas for fentanyl, oxycodone, hydrocodone, oxymorphone, and hydromorphone.
Additionally, if the DEA increases the production quota of fentanyl, oxycodone, hydrocodone, oxymorphone, or hydromorphone, then it must explain why the public health benefits of increasing the quota outweigh the consequences of potential diversion.